AVROBIO, Inc. announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare diseases, with a focus on lysosomal and neurogenetic disorders. She has been heavily involved in guiding the development of new therapies for rare diseases, including Pompe disease. A board-certified neurologist and fellow of the American Academy of Neurology, Dr. Escolar previously served as chief medical officer at miRagen Therapeutics, a clinical-stage company developing microRNA therapeutics for leading indications in rare diseases. She also served as the chief medical officer of Akashi Therapeutics, Inc., the principal medical consultant for Acceleron Pharma’s muscular dystrophy program and a senior medical consultant and advisory board member for the muscular dystrophy programs at Shire, Plc. Dr. Escolar was the principal medical consultant for Genzyme’s pivotal trial for Myozyme, an enzyme replacement therapy approved to treat adult-onset Pompe disease.